Last A$5.03 AUD
Change Today +0.03 / 0.60%
Volume 450.6K
As of 2:10 AM 08/29/14 All times are local (Market data is delayed by at least 15 minutes).

mesoblast ltd (MSB) Snapshot

Open
A$5.10
Previous Close
A$5.00
Day High
A$5.13
Day Low
A$4.89
52 Week High
11/1/13 - A$6.80
52 Week Low
07/28/14 - A$3.91
Market Cap
1.6B
Average Volume 10 Days
709.4K
EPS TTM
A$-0.25
Shares Outstanding
321.6M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for MESOBLAST LTD (MSB)

Related News

No related news articles were found.

mesoblast ltd (MSB) Details

Mesoblast Limited, a biotechnology company, is engaged in the research and development of its propriety stem cell technologies for use in the treatment of multiple major disease states and other medical conditions. The company’s cell-based core technologies include immunoselected mesenchymal precursor cells (MPCs), culture-expanded mesenchymal stem cells (MSCs), dental pulp stem cells, and expanded hematopoietic stem cells. Its lead products include MSC-100-IV, which is used for the treatment of steroid refractory acute graft versus host disease and biologic refractory crohn’s disease; MPC-06-ID that is used for the treatment of chronic low back pain; and MPC-150-IM, which is used for congestive heart failure treatment. The company also offers supporting products, such as MPC-300-IV, an intravenously administered MPCs that are used for the treatment of type 2 diabetes, liver/kidney complications, and rheumatoid arthritis; MPC-25-IC, which is used for the treatment of acute myocardial infarction; MPC-25-Osteo for use in surgical bone repair; MPC-CBE that is used in bone marrow transplantations; and MPC-MICRO-IO for use in age-related macular degeneration treatment. In addition, it provides various products for the treatment of ophthalmology diseases, neurological diseases, lung diseases, etc. The company has strategic alliances with Lonza Group for clinical and long-term commercial production of its off-the-shelf (allogeneic) adult stem cell products; and Teva Pharmaceutical Industries Ltd. for the development and commercialization of its immunoselected MPCsthat that are used for cardiac and vascular diseases. It has operations in Australia, the United States, and Singapore. Mesoblast Limited was founded in 2004 and is headquartered in Melbourne, Australia.

115 Employees
Last Reported Date: 08/25/14
Founded in 2004

mesoblast ltd (MSB) Top Compensated Officers

Founder, Chairman of Scientific Advisory Boar...
Total Annual Compensation: A$1.8M
Compensation as of Fiscal Year 2014.

mesoblast ltd (MSB) Key Developments

Mesoblast Reports Earnings Results for the Year Ended June 30, 2014

Mesoblast reported earnings results for the year ended June 30, 2014. For the year, the company reported revenue from continuing operations of AUD 26.0 million against AUD 28.8 million a year ago. Loss after tax was AUD 81.0 million against AUD 61.6 million a year ago.

Mesoblast Limited to Report Fiscal Year 2014 Results on Aug 26, 2014

Mesoblast Limited announced that they will report fiscal year 2014 results on Aug 26, 2014

Mesoblast Limited Announces Executive Changes

Mesoblast Limited announced the appointment of pharmaceutical executive Mr. Paul Hodgkinson as Chief Financial Officer. Mr. Hodgkinson has broad and high-level international pharmaceutical experience in all aspects of finance, strategic planning, business development and licensing, manufacturing and supply chain, and procurement. From 2011 to 2014, Mr. Hodgkinson was Chief Financial Officer and had full financial responsibility for the Novartis ANZ Group of companies and divisions comprising Pharmaceuticals, Alcon, Sandoz, Vaccines and Diagnostics, Consumer and Animal Health. Previously, he held a number of leadership roles with AstraZeneca in the United Kingdom, including Global Licensing Finance Director, before being appointed Chief Financial Officer for AstraZeneca Australia from 2006 to 2011. After seven years in Mesoblast's executive team as Chief Financial Officer and Company Secretary, Ms. Jenni Pilcher will depart on August 31, 2014 to take up a new role with an Australian biotechnology company as Chief Financial Officer.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
MSB:AU A$5.03 AUD +0.03

MSB Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Biorestorative Therapies Inc $0.33 USD +0.01
IntelliCell BioSciences Inc $0.0018 USD +0.0002
International Stem Cell Corp $0.10 USD -0.005
View Industry Companies
 

Industry Analysis

MSB

Industry Average

Valuation MSB Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 43.2x
Price/Book 2.8x
Price/Cash Flow NM Not Meaningful
TEV/Sales 37.9x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact MESOBLAST LTD, please visit www.mesoblast.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.